

Long-term effects of intensive multifactorial therapy in type 2 diabetes in primary care: 10-year follow-up of the cluster-randomised trial

Lancet Diabetes and Endocrinology, the
7, 925-937

DOI: [10.1016/s2213-8587\(19\)30349-3](https://doi.org/10.1016/s2213-8587(19)30349-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ADDITION-Europe: the first decade and beyond. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 891-893.	5.5	2
2	Patient-reported outcomes after 10-year follow-up of intensive, multifactorial treatment in individuals with screen-detected type 2 diabetes: the ADDITION-Europe trial. <i>Diabetic Medicine</i> , 2020, 37, 1509-1518.	1.2	1
3	Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3025-3035.	1.8	22
4	A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. <i>Primary Care Diabetes</i> , 2021, 15, 31-51.	0.9	27
5	Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial. <i>Diabetes Care</i> , 2021, 44, 164-173.	4.3	31
6	An automatic detection system of diabetic retinopathy using a hybrid inductive machine learning algorithm. <i>Personal and Ubiquitous Computing</i> , 2023, 27, 751-765.	1.9	25
7	Patients with rare endocrine conditions have corresponding views on unmet needs in clinical research. <i>Endocrine</i> , 2021, 71, 561-568.	1.1	4
8	Diabetic Polyneuropathy Early in Type 2 Diabetes Is Associated With Higher Incidence Rate of Cardiovascular Disease: Results From Two Danish Cohort Studies. <i>Diabetes Care</i> , 2021, 44, 1714-1721.	4.3	8
9	High adherence to recommended diabetes follow-up procedures by general practitioners is associated with lower estimated cardiovascular risk. <i>Diabetic Medicine</i> , 2021, 38, e14586.	1.2	6
10	Screening for Prediabetes and Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 736.	3.8	223
11	New USPSTF Recommendations for Screening for Prediabetes and Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 701.	3.8	7
12	Screening for Prediabetes and Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 744.	3.8	40
13	Achieving sensible targets for a diabetes care cascade in LMICs. <i>The Lancet Global Health</i> , 2021, 9, e1481-e1482.	2.9	0
14	Screening for Diabetes and Prediabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 369-385.	1.2	26
15	The effect of training GPs in motivational interviewing on incident cardiovascular disease and mortality in people with screen-detected diabetes. Results from the ADDITION-Denmark randomised trial. <i>BJGP Open</i> , 2020, 4, bjgpopen20X101012.	0.9	1
16	2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. <i>Primary Care Diabetes</i> , 2022, 16, 223-244.	0.9	15
17	Vessel Segmentation Approach with Deep Neural Network Model for Detection of Diabetic Retinopathy. , 2022, , .		1
18	Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1472-1488.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Long-term effects of intensive multifactorial treatment on aortic stiffness and central hemodynamics after 13 years with screen-detected type 2 diabetes: the ADDITION-Denmark trial. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	1.2	0
20	Ten-Year Effectiveness of the Multidisciplinary Risk Assessment and Management Programme “Diabetes Mellitus (RAMP-DM) on Macrovascular and Microvascular Complications and All-Cause Mortality: A Population-Based Cohort Study. <i>Diabetes Care</i> , 2022, 45, 2871-2882.	4.3	10
21	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan “2022 Update. <i>Endocrine Practice</i> , 2022, 28, 923-1049.	1.1	146
22	Long-Term Association between Intensive Medical Treatment and the Incidence of Cardiovascular Outcomes in Patients with Dyslipidemia: an Observational Study. <i>Cardiology and Therapy</i> , 0, , .	1.1	0
23	Long-term Effect of Lifestyle Interventions on the Cardiovascular and All-Cause Mortality of Subjects With Prediabetes and Type 2 Diabetes: A Systematic Review and Meta-analysis. <i>Diabetes Care</i> , 2022, 45, 2787-2795.	4.3	9
24	Observational Evaluations of Disease Management Programs for Diabetes: The Proof Is in the Concept. <i>Diabetes Care</i> , 2022, 45, 2808-2810.	4.3	0
25	The STC2 “ PAPP-A “ IGFBP4 “ IGF1 axis and associations to mortality and CVD in T2D. <i>Endocrine Connections</i> , 2023, , .	0.8	2
26	Intensified Multifactorial Intervention in Patients with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 185-197.	1.8	8
27	Blood pressure control for diabetic retinopathy. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	6
28	Improving health outcomes of people with diabetes: target setting for the WHO Global Diabetes Compact. <i>Lancet</i> , The, 2023, 401, 1302-1312.	6.3	30
29	Effect of Intensive Glycemic Control on Myocardial Infarction Outcome in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Journal of Diabetes Research</i> , 2023, 2023, 1-11.	1.0	0
30	Cancer Outcomes Among Prediabetes and Type 2 Diabetes Populations With Dietary and Physical Activity “based Lifestyle Interventions. <i>Journal of Clinical Endocrinology and Metabolism</i> , 0, , .	1.8	3
34	Exploring mechanisms underlying diabetes comorbidities and strategies to prevent vascular complications. <i>Diabetology International</i> , 0, , .	0.7	0